Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

Nov. 19, 2024 — Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new ... Earlier Diabetes Diagnosis Linked to Dementia Risk Nov. 19, 2024 ...

Individuals who suffer head trauma from sports, accidents, or other causes often go on to develop neurodegenerative diseases ...

Vitamin D also helps clear beta amyloid, a protein that plays a role in Alzheimer’s disease, Merrill points out. This is “the ...

A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...

Summary: A new study has identified a biomarker, DTI-ALPS, which connects glymphatic system dysfunction to vascular dementia.